Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Imago BioSciences announced that CEO Hugh Y. Rienhoff, Jr., M.D. will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Dr. Rienhoff is scheduled for a discussion on Leukemias and Myeloproliferative Neoplasms on March 7 at 10:30 a.m. ET. The event will be available via live webcast on the company's website, with a replay accessible for 30 days post-event. Imago, focused on treating myeloproliferative neoplasms, is advancing its lead candidate, Bomedemstat, in Phase 2 trials.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in the Cowen 42^nd Annual Health Care Conference, taking place March 7-9, 2022.

Dr. Rienhoff is scheduled to participate in the “Leukemias and Myeloproliferative Neoplasms” corporate panel discussion, on Monday, March 7, at 10:30 a.m. Eastern Time.

Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.imagobio.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Contacts

INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com

MEDIA
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

Source: ​Imago BioSciences

FAQ

What conference will Imago BioSciences participate in on March 7, 2022?

Imago BioSciences will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022.

What is the focus of the panel discussion featuring Imago's CEO on March 7?

The panel discussion will focus on Leukemias and Myeloproliferative Neoplasms.

Where can I access the live webcast for Imago BioSciences' conference participation?

The live webcast can be accessed via the Investor Relations section of Imago BioSciences' website.

What is Bomedemstat and its relevance to Imago BioSciences?

Bomedemstat is Imago's lead candidate, targeting myeloproliferative neoplasms and currently in Phase 2 clinical trials.

What designations has Bomedemstat received from the FDA?

Bomedemstat has received U.S. FDA Orphan Drug and Fast Track Designation for the treatment of essential thrombocythemia and myelofibrosis.